2 active not recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
Follow CD20 Positive: new trials by email Literature Review of CD20 Positive trials Research Report on CD20 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Acalabrutinib, Venetoclax - Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 32 | 2019-08-13 | 2026-08-10 |
| Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Rituximab - CCND1 Positive, CCND2 Positive | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 113 | 2013-07-15 | 2026-07-08 |
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
CT-P10 (1) · Rituximab (1) · acalabrutinib (1) · ibrutinib (1) · venetoclax (1)
M.D. Anderson Cancer Center (2)
United States (2)